Highly immunosuppressive myeloid cells correlate with early relapse after allogeneic stem cell transplantation

Archive ouverte

Notarantonio, Anne-Béatrice | Bertrand, Allan | Piucco, Romain | Fievet, Ghislain | Sartelet, Hervé | Boulangé, Laura | de Isla, Natalia | de Carvalho-Bittencourt, Marcelo | Hergalant, Sébastien | Rubio, Marie-Thérèse | d'Aveni, Maud

Edité par CCSD ; BMC -

International audience. Abstract Background Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for myeloid malignancies such as some acute myeloid leukemias (AML) and high-risk myelodysplastic syndromes (MDS). It aims to eradicate the malignant clone using immunocompetent donor cells (graft-versus-leukemia effect, GVL). Unfortunately, relapse is the primary cause of transplant failure mainly related on HLA loss or downregulation and upregulation of inhibitory ligands on blasts which result in donor immune effector dysfunctions. Methods Between 2018 and 2021, we conducted a monocentric prospective study including 61 consecutive patients transplanted for AML or high-risk MDS. We longitudinally investigated immune cells at days + 30, + 90 and + 180 post-transplant from bone marrow and peripheral blood. We assessed the dynamics between myeloid derived suppressor cells (MDSCs) and T-cells. Results Among the 61 patients, 45 did not relapse over the first 12 months while 16 relapsed during the first year post-transplant. Through months 1 to 6, comparison with healthy donors revealed an heterogenous increase in MDSC frequency. In all recipients, the predominant MDSC subset was granulocytic with no specific phenotypic relapse signature. However, in relapsed patients, in vitro and in vivo functional analyses revealed that MDSCs from peripheral blood were highly immunosuppressive from day + 30 onwards, with an activated NLRP3 inflammasome signature. Only circulating immunosuppressive MDSCs were statistically correlated to circulating double-positive Tim3+LAG3+ exhausted T cells. Conclusion Our simple in vitro functional assay defining MDSC immunosuppressive properties might serve as an early biomarker of relapse and raise the question of new preventive treatments targeting MDSCs in the future. Trial registration NCT03357172

Suggestions

Du même auteur

Description d'une nouvelle signature immunitaire dans le contexte de la rechute après allogreffe de Cellules Souches Hématopoïétiques

Archive ouverte | Notarantonio, Anne-Béatrice | CCSD

International audience. CONTEXTEL'allogreffe de cellules souches hématopoïétiques est la seule immunothérapie curative des leucémies aiguës myéloïdes (LAM)réfractaires. La rechute est une complication mortelle et su...

Role of myeloid derived suppressive cells in the exhaust of tumor cells to the effect of graft versus leukemia (GVL), and control of graft-versus-host (GVH) response after allogeneic human hematopoietic stem cells. Rôle des cellules myéloïdes suppressives dans l’échappement des cellules tumorales à l’effet de la greffe contre la leucémie (GVL) et le contrôle de la réaction du greffon contre l’hôte (GVH) après allogreffe de cellules souches hématopoïétiques humaines

Archive ouverte | Notarantonio, Anne-Béatrice | CCSD

Thèse confidentielle jusqu’au 25 novembre 2026. A la sortie de confidentialité, l'auteur de la thèse a souhaité limiter l'accès aux membres de l'Enseignement supérieur français.. The allogeneic hematopoietic stem ce...

Les cellules X : Un nouvel espoir dans la prise en charge de la maladie du greffon contre l’hôte en allogreffe de cellules souches hématopoïétiques

Archive ouverte | Notarantonio, Anne-Béatrice | CCSD

International audience

Chargement des enrichissements...